LMAT logo

LeMaitre Vascular (LMAT) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

19 October 2006

Indexes:

Not included

Description:

LeMaitre Vascular, Inc. is a medical equipment manufacturing company in the United States. Its products are used by vascular surgeons and specialist physicians in invasive procedures. The company offers angioscopes, fiber-optic catheters used for viewing the lumen of blood vessels; embolic catheters for removing clots from arteries or veins; occlusion catheters that temporarily block blood flow; perfusion catheters for temporary blood and other fluid perfusion into the vascular system; and thrombectomy catheters equipped with a silicone balloon for removing clots in the venous system. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.

Key Details

Price

$105.80

TTM Dividend Yield

0.60%(-42.86% YoY)

Annual Revenue

$193.48 M(+19.69% YoY)

Annual EPS

$1.34(+44.09% YoY)

PE Ratio

57.81(+31.12% YoY)

Beta

1.09

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Oct 31, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Nov 21, 2024
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

01 Nov '24 Oppenheimer
Outperform
01 Nov '24 Barrington Research
Outperform
15 Oct '24 Cantor Fitzgerald
Neutral
20 Sept '24 Barrington Research
Outperform
20 Aug '24 JMP Securities
Market Outperform
02 Aug '24 Barrington Research
Outperform
03 May '24 JMP Securities
Market Outperform
03 May '24 Barrington Research
Outperform
26 Apr '24 Stifel
Buy
28 Feb '24 Barrington Research
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

LeMaitre to Participate at Upcoming Investor Conferences in December
LeMaitre to Participate at Upcoming Investor Conferences in December
LeMaitre to Participate at Upcoming Investor Conferences in December
LMAT
globenewswire.com25 November 2024

BURLINGTON, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two upcoming investor conferences in December.

LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
LMAT
seekingalpha.com03 November 2024

LeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year and double-digit CAGR over the past five years are particularly appealing. With a high-margin, low-competition niche and accelerating geographic expansion, LeMaitre remains well-positioned for sustained growth.

LeMaitre to Participate at Upcoming Investor Conferences in November
LeMaitre to Participate at Upcoming Investor Conferences in November
LeMaitre to Participate at Upcoming Investor Conferences in November
LMAT
globenewswire.com01 November 2024

BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in November.

LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript
LMAT
seekingalpha.com31 October 2024

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q3 2024 Earnings Conference Call October 33, 2024 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Suraj Kalia - Oppenheimer Rick Wise - Stifel Brett Fishbin - KeyBanc Jason Wittes - Roth Danny Stauder - Citizens JMP Michael Petusky - Barrington Research Frank Takkinen - Lake Street Capital Markets Jim Sidoti - Sidoti & Company Ross Osborn - Cantor Fritzgerald Operator Welcome to the LeMaitre Vascular Q3 2024 Financial Results Conference Call.

LeMaitre Vascular (LMAT) Surpasses Q3 Earnings and Revenue Estimates
LeMaitre Vascular (LMAT) Surpasses Q3 Earnings and Revenue Estimates
LeMaitre Vascular (LMAT) Surpasses Q3 Earnings and Revenue Estimates
LMAT
zacks.com31 October 2024

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.33 per share a year ago.

LeMaitre Q3 2024 Financial Results
LeMaitre Q3 2024 Financial Results
LeMaitre Q3 2024 Financial Results
LMAT
globenewswire.com31 October 2024

BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance.

LeMaitre Will Announce Third Quarter 2024 Earnings Results October 31, 2024
LeMaitre Will Announce Third Quarter 2024 Earnings Results October 31, 2024
LeMaitre Will Announce Third Quarter 2024 Earnings Results October 31, 2024
LMAT
globenewswire.com15 October 2024

BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

All You Need to Know About LeMaitre (LMAT) Rating Upgrade to Strong Buy
All You Need to Know About LeMaitre (LMAT) Rating Upgrade to Strong Buy
All You Need to Know About LeMaitre (LMAT) Rating Upgrade to Strong Buy
LMAT
zacks.com23 September 2024

LeMaitre (LMAT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LeMaitre to Participate at Upcoming Investor Conferences in September
LeMaitre to Participate at Upcoming Investor Conferences in September
LeMaitre to Participate at Upcoming Investor Conferences in September
LMAT
globenewswire.com27 August 2024

BURLINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in September.

LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why
LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why
LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why
LMAT
zacks.com06 August 2024

LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

FAQ

  • What is the primary business of LeMaitre Vascular?
  • What is the ticker symbol for LeMaitre Vascular?
  • Does LeMaitre Vascular pay dividends?
  • What sector is LeMaitre Vascular in?
  • What industry is LeMaitre Vascular in?
  • What country is LeMaitre Vascular based in?
  • When did LeMaitre Vascular go public?
  • Is LeMaitre Vascular in the S&P 500?
  • Is LeMaitre Vascular in the NASDAQ 100?
  • Is LeMaitre Vascular in the Dow Jones?
  • When was LeMaitre Vascular's last earnings report?
  • When does LeMaitre Vascular report earnings?
  • Should I buy LeMaitre Vascular stock now?

What is the primary business of LeMaitre Vascular?

LeMaitre Vascular, Inc. is a medical equipment manufacturing company in the United States. Its products are used by vascular surgeons and specialist physicians in invasive procedures. The company offers angioscopes, fiber-optic catheters used for viewing the lumen of blood vessels; embolic catheters for removing clots from arteries or veins; occlusion catheters that temporarily block blood flow; perfusion catheters for temporary blood and other fluid perfusion into the vascular system; and thrombectomy catheters equipped with a silicone balloon for removing clots in the venous system. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.

What is the ticker symbol for LeMaitre Vascular?

The ticker symbol for LeMaitre Vascular is NASDAQ:LMAT

Does LeMaitre Vascular pay dividends?

Yes, LeMaitre Vascular pays dividends. The last payment was $0.16, with an ex-dividend date on 21 November 2024

What sector is LeMaitre Vascular in?

LeMaitre Vascular is in the Healthcare sector

What industry is LeMaitre Vascular in?

LeMaitre Vascular is in the Medical Instruments & Supplies industry

What country is LeMaitre Vascular based in?

LeMaitre Vascular is headquartered in United States

When did LeMaitre Vascular go public?

LeMaitre Vascular's initial public offering (IPO) was on 19 October 2006

Is LeMaitre Vascular in the S&P 500?

No, LeMaitre Vascular is not included in the S&P 500 index

Is LeMaitre Vascular in the NASDAQ 100?

No, LeMaitre Vascular is not included in the NASDAQ 100 index

Is LeMaitre Vascular in the Dow Jones?

No, LeMaitre Vascular is not included in the Dow Jones index

When was LeMaitre Vascular's last earnings report?

LeMaitre Vascular's most recent earnings report was on 31 October 2024

When does LeMaitre Vascular report earnings?

The next expected earnings date for LeMaitre Vascular is 27 February 2025

Should I buy LeMaitre Vascular stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions